Hu Liguo, Pan Jianhui, Zhang Shantang, Yu Jinjing, He Keqiang, Shu Shuhua, Wang Ruiting
Department of Anesthesiology, Anhui Provincial Hospital, Anhui Medical University, Hefei 230001, Anhui, China.
Department of Anesthesiology, Anhui Provincial Hospital, Anhui Medical University, Hefei 230001, Anhui, China.
Taiwan J Obstet Gynecol. 2017 Aug;56(4):521-526. doi: 10.1016/j.tjog.2016.09.010.
This study aims to describe the administration of propofol in combination with remifentanil for the induction of general anesthesia during cesarean section (CS). Our aim was to evaluate its impact on the drug concentrations of the maternal and neonatal blood at different induction of anesthesia to delivery (I-D) intervals as well as its effect on newborns.
In this double-blind randomized controlled study, patients undergoing elective CS were administered anesthesia at short (n = 20) or long (n = 20) I-D intervals. Anesthesia was induced with 1 mg/kg propofol and 1 μg/kg remifentanil and maintained by continuous infusion of 3 mg/kg/h propofol and 7 μg/kg/h remifentanil.
The mean plasma propofol concentrations at delivery in the maternal arterial (MA) blood and the fetal umbilical arterial (UA) and venous (UV) blood in the short I-D interval group were 1.91, 1.17, and 0.51 μg/mL, respectively, while those in the long I-D interval group were 1.57, 1.07, and 0.61 μg/mL, respectively. The mean plasma remifentanil concentrations at delivery in the MA, UA, and UV in the short I-D interval group were 2.25, 1.43, and 0.65 ng/mL, respectively, and those in the long I-D interval group were 1.96, 1.25, and 0.75 ng/mL, respectively. There were no statistically significant differences in the neonatal Apgar scores and neurological adaptive capacity scores between the two groups.
It is safe to administer propofol in combination with remifentanil by continuous infusion after the bolus dose for the induction of anesthesia during cesarean section. Prolonging the I-D interval within a certain limit will not have any significant influence on the fetus.
本研究旨在描述剖宫产术中丙泊酚联合瑞芬太尼用于全身麻醉诱导的情况。我们的目的是评估其在不同麻醉诱导至分娩(I-D)间隔时间对母体和新生儿血液药物浓度的影响以及对新生儿的作用。
在这项双盲随机对照研究中,接受择期剖宫产的患者在短(n = 20)或长(n = 20)I-D间隔时间接受麻醉。麻醉诱导采用1mg/kg丙泊酚和1μg/kg瑞芬太尼,并通过持续输注3mg/kg/h丙泊酚和7μg/kg/h瑞芬太尼维持。
短I-D间隔时间组产妇动脉(MA)血、胎儿脐动脉(UA)血和脐静脉(UV)血中分娩时丙泊酚的平均血浆浓度分别为1.91、1.17和0.51μg/mL,而长I-D间隔时间组分别为1.57、1.07和0.61μg/mL。短I-D间隔时间组MA、UA和UV中分娩时瑞芬太尼的平均血浆浓度分别为2.25、1.43和0.65ng/mL,长I-D间隔时间组分别为1.96、1.25和0.75ng/mL。两组新生儿阿普加评分和神经适应能力评分无统计学显著差异。
剖宫产麻醉诱导推注剂量后持续输注丙泊酚联合瑞芬太尼是安全的。在一定限度内延长I-D间隔时间对胎儿无显著影响。